---
title: "Sumitomo treats first patient in Phase I/IIa trial of DSP-3077"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295900454.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-13T09:49:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295900454.md)
  - [en](https://longbridge.com/en/news/295900454.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295900454.md)
generator: "portal-rs"
---

# Sumitomo treats first patient in Phase I/IIa trial of DSP-3077

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4506.JP](https://longbridge.com/en/quote/4506.JP.md)

## Related News & Research

- [Sumitomo Pharma (TSE:4506) Reports Strong First Quarter Earnings, Is The Discount Too Deep?](https://longbridge.com/en/news/295441766.md)
- [Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast](https://longbridge.com/en/news/294406043.md)
- [Sumitomo Pharma Q1 FY27 net profit rises 51.7% to JPY 17 billion; revenue increases 19.9% to JPY 129.5 billion](https://longbridge.com/en/news/294464374.md)
- [Sumitomo Pharma, Novo Nordisk’s Wegovy wins Japan approval for MASH indication](https://longbridge.com/en/news/290268404.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**